Why Britain's mid-cap stocks crashed

The FTSE 100, Britain’s main index, has had a shaky few days. But the FTSE 250, Britain's index of mid-cap stocks, has really taken a battering.

The FTSE 100, Britain's main index, has had a shaky few days. But the FTSE 250 index has really taken a battering, say Michael Hunter and Rochelle Toplensky in the FT. Last Friday and Monday it slid by a total of 14%, its worst two-day loss since the crash of 1987. The blue chips fell by around 5% over the same period. The trouble is that the FTSE 250 is a much better reflection of the UK economy than its bigger counterpart. It is largely made up of medium-sized manufacturers, service companies and retailers. The FTSE 100 is full of large multinationals, and is unusually skewed towards commodities firms.

The blue chips make 75% of their sales outside the UK, and the weakness of the pound helps those who earn their revenue in

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
Andrew Van Sickle
Editor, MoneyWeek

Andrew is the editor of MoneyWeek magazine. He grew up in Vienna and studied at the University of St Andrews, where he gained a first-class MA in geography & international relations.

After graduating he began to contribute to the foreign page of The Week and soon afterwards joined MoneyWeek at its inception in October 2000. He helped Merryn Somerset Webb establish it as Britain’s best-selling financial magazine, contributing to every section of the publication and specialising in macroeconomics and stockmarkets, before going part-time.

His freelance projects have included a 2009 relaunch of The Pharma Letter, where he covered corporate news and political developments in the German pharmaceuticals market for two years, and a multiyear stint as deputy editor of the Barclays account at Redwood, a marketing agency.

Andrew has been editing MoneyWeek since 2018, and continues to specialise in investment and news in German-speaking countries owing to his fluent command of the language.